Search | Clinical Trials Finder

Conditions: Pneumococcal Vaccines
Interventions: 31-valent pneumococcal conjugate vaccine, PCV20; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 752 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 30
States / cities: Chinle, Arizona • Phoenix, Arizona • Whiteriver, Arizona + 27 more

Conditions: Alzheimer's Disease
Interventions: SB-742457; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Respiratory Syncytial Virus (RSV), Infectious Disease
Interventions: JCXH-108, Placebo; Biological · Other
Lead sponsor: Immorna Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Jupiter, Florida • New Orleans, Louisiana • St Louis, Missouri

Conditions: Healthy
Interventions: MT400; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Young Volunteers, Healthy Elderly Volunteers
Interventions: AZD3293, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Placebo, JNJ-41443532; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Cypress, California

Conditions: Meningococcal Vaccine
Interventions: MenABCWY, Saline, rLP2086, MenACWY-CRM; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 1,610 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntsville, Alabama • Fountain Hills, Arizona + 45 more

Conditions: Excessive Daytime Sleepiness
Interventions: ORX142 Tablets, Placebo Tablets; Drug · Other
Lead sponsor: Centessa Pharmaceuticals (UK) Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Lincoln, Nebraska • Eatontown, New Jersey • New York, New York

Conditions: Aging, Frailty, Exercise Tolerance, Healthy Male and Female Subjects
Interventions: NMN, betaine, low-dose hydrogen peroxide (EGA), Nicotinamide Mononucleotide (NMN), Placebo; Dietary Supplement
Lead sponsor: Scott Silveira; Other
Eligibility: 60 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Tuberculosis
Interventions: Moxifloxacin, PA-824, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteers
Interventions: TAK-915 suspension, Midazolam, Placebo, TAK-915 tablet; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Age-Related Macular Degeneration, Diabetic Retinopathy, Von Hippel-Lindau Syndrome, Retinal Disease, Retinal Vein Occlusion
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 2 Years to 120 Years
Enrollment: 650 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pneumonia, Bacterial, Healthy Volunteers, Pneumococcal Disease
Interventions: ASP3772, PCV13, PPSV23; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 630 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 26
States / cities: Banning, California • San Diego, California • San Marcos, California + 21 more

Conditions: Pneumococcal Vaccines
Interventions: 31 valent pneumococcal conjugate vaccine, PCV20, PCV21; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4,049 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 30
States / cities: Birmingham, Alabama • Chinle, Arizona • Whiteriver, Arizona + 27 more

Conditions: Healthy Elderly Volunteers
Interventions: HT-0712; Drug
Lead sponsor: Dart NeuroScience, LLC; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Upton, New York

Conditions: Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
Interventions: RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Placebo, Control Vaccine 1; Biological · Other
Lead sponsor: Sanofi; Industry
Eligibility: 60 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 17
States / cities: Gadsden, Alabama • Scottsdale, Arizona • Long Beach, California + 14 more

Conditions: Healthy Elderly, Parkinson Disease
Interventions: IkT-148009, Placebo; Drug
Lead sponsor: ABLi Therapeutics, Inc.; Industry
Eligibility: 55 Years to 70 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Long Beach, California • Hallandale, Florida • Farmington Hills, Michigan + 1 more

Conditions: Healthy Volunteers
Interventions: Purified Inactivated Zika Virus Vaccine (PIZV), Placebo; Biological · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 5
States / cities: Oakland Park, Florida • Meridian, Idaho • Wichita, Kansas + 2 more

Conditions: Healthy Volunteers
Interventions: selonabant, placebo; Drug
Lead sponsor: Anebulo Pharmaceuticals; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: Sham Stimulation, Transcranial Direct Current Stimulation; Device
Lead sponsor: University of Florida; Other
Eligibility: 65 Years to 90 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Gainesville, Florida

Conditions: Alzheimer's Disease
Interventions: BMS-984923, Placebo; Drug
Lead sponsor: Allyx Therapeutics; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: New Haven, Connecticut • West Bend, Wisconsin

Conditions: Healthy Volunteers
Interventions: HSV529, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Participants
Interventions: BMS-986368; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Schizophrenia, Alzheimer Disease
Interventions: Placebo matching BI 409306 25 mg, Placebo matching BI 409306 50 mg, BI 409306 25 mg, BI 409306 50 mg; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: La Jolla, California • Eatontown, New Jersey • Austin, Texas

Search by objective public record fields.

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers.

A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV

Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT 400 or Naproxen Sodium Tablets

A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects

JNJ-41443532 Sex, Race, and Age Pharmacokinetic (PK) Study

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers

Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study

National Eye Institute Biorepository for Retinal Diseases

A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

Study of the Inhibition of [11C]R-rolipram Binding to Brain Phosphodiesterase - 4 (PDE-4) by HT-0712

Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients

A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults

I.V. Selonabant in Healthy Adult Subjects

Neuromodulation of Cognition in Older Adults

A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease

Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers